Woodmont Investment Counsel LLC bought a new stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 5,574 shares of the company’s stock, valued at approximately $560,000.
Other large investors have also added to or reduced their stakes in the company. Balance Wealth Partners LLC bought a new position in iShares U.S. Pharmaceuticals ETF in the third quarter worth about $42,000. Root Financial Partners LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 3rd quarter valued at about $51,000. Congress Asset Management Co. bought a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 3rd quarter valued at about $56,000. Trust Co. of Vermont purchased a new position in shares of iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth approximately $60,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF in the 3rd quarter worth approximately $64,000.
iShares U.S. Pharmaceuticals ETF Stock Down 0.6%
NYSEARCA IHE opened at $106.92 on Tuesday. The firm has a market cap of $1.60 billion, a PE ratio of 17.75 and a beta of 0.47. The company has a 50 day moving average price of $102.42 and a 200 day moving average price of $94.85. iShares U.S. Pharmaceuticals ETF has a 52 week low of $75.03 and a 52 week high of $109.43.
iShares U.S. Pharmaceuticals ETF Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Stories
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
